Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib discontinuation in pediatric CML with sustained complete molecular response
NL-OMON39021Phase 4Active, not recruiting
- Sponsor
- SKion
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by SKion. Primary endpoints: Molecular relapse-free survival at 6 months, Molecular relapse-free survival at 24 months and 1 more. Started Jun 2014; status: active, not recruiting.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON39021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39021.